FOCIS New Investigator Travel Awards (2004-2008)

FOCIS 新研究者旅行奖（2004-2008 年）

• 批准号: 7470548
• 负责人: CHARLES GARRISON FATHMAN
• 金额: $ 2.8万
• 依托单位: FEDERATION/CLINICAL IMMUNOLOGY SOCIETIES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7470548
• 关键词: Accounting; Applied Research; Asthma; Autoimmune Diseases; Award; Basic Science; Biotechnology; Clinic; Clinical; Clinical Immunology; Communicable Diseases; Critiques; Diagnosis; Discipline; Disease; Drug Industry; Evolution; Faculty; Fostering; Functional disorder; Funding; Goals; Graft Rejection; Grant; Hypersensitivity; Immune; Immunology; Incubators; Laboratories; Learning; Link; Malignant Neoplasms; Minority; Modeling; Oral; Organ; Pharmacologic Substance; Postdoctoral Fellow; Range; Research; Research Personnel; Science; Scientist; Societies; Standards of Weights and Measures; Travel; United States; Woman; Work; abstracting; base; day; demographics; medical specialties; member; multidisciplinary; novel; novel therapeutics; posters; pre-doctoral; programs; success; translational approach

DESCRIPTION (provided by applicant): This grant request is for fifty (50) Travel Awards of $1,500 each for a total of $75,000, increasing by 5% annually, for new investigators (pre-doctoral fellows, post-doctoral fellows and junior faculty members) from the United States to attend the Federation of Clinical Immunology Societies (FOCIS) annual meeting. This grant request accounts for only 50% of the funding for FOCIS Travel Awards. Additional funding will be solicited from pharmaceutical and biotechnology companies. The FOCIS annual meeting provides a scientific forum to foster the cross-disciplinary approach required to understand and treat immune-based diseases as the discipline of clinical immunology evolves. The evolution is a reflection of the shared pathophysiology of many diseases, including: autoimmune diseases, cancer, allergy/asthma, infectious diseases, immune deficiency, and transplant rejection. While clinicians necessarily remain linked to diseases associated with their own specialty, the immunological sciences underlying recent advances in diagnosing and treating these diverse diseases are multidisciplinary and cut across standard clinical boundaries. The ultimate goal of the FOCIS annual meeting is to create a better understanding of the shared pathophysiological underpinnings of clinical immunology and the new therapeutic approaches suggested by these novel relationships, including the increasingly widespread use of biologics in therapy. The FOCIS annual meeting offers new investigators an opportunity to understand where breakthroughs in basic science models are coming into the clinic, and how clinical therapies can be applied in completely different fields. In addition to highlighting the best science in the field, the FOCIS annual meeting is an incubator for developing scientists and practitioners alike to meet with one another along with representatives of the relevant biotechnology and pharmaceutical industry whose combined support is invaluable to the success of this meeting. Each day includes poster and oral abstract presentations to give young scientists as well as senior investigators the chance to have their work presented and critiqued. By sharing discoveries with one another, delegates acquire new ideas for research and applied science from disciplines to which they would otherwise not be exposed at disease- or organ-specific meetings. The FOCIS annual meeting is an ideal forum for new investigators to learn about the different translational approaches that are bridging the basic immunology laboratories with clinical practice. In addition to encouraging the participation of new investigators, FOCIS recognizes the importance of participation from a wide range of demographics. Every effort has been made to include a diverse representation within the FOCIS Steering Committee and the annual meeting's scientific program. At the third annual FOCIS meeting, 36% of the meeting attendees were woman, 25% were new investigators, and 25% were minority.

描述（由申请人提供）：本补助金申请为五十（50）个旅行奖，每个1，500美元，总计75，000美元，每年增加5%，用于来自美国的新研究人员（博士前研究员，博士后研究员和初级教师）参加临床免疫学学会联合会（FOCIS）年会。这笔赠款申请仅占FOCIS旅行奖资金的50%。将向制药和生物技术公司寻求额外资金。 FOCIS年会提供了一个科学论坛，以促进理解和治疗免疫性疾病所需的跨学科方法，随着临床免疫学学科的发展。这种演变反映了许多疾病的共同病理生理学，包括：自身免疫性疾病、癌症、过敏/哮喘、传染病、免疫缺陷和移植排斥。虽然临床医生必然与自己的专业相关的疾病保持联系，但在诊断和治疗这些不同疾病方面的最新进展背后的免疫学科学是多学科的，并且跨越了标准的临床界限。FOCIS年会的最终目标是更好地理解临床免疫学的共同病理生理学基础以及这些新关系所建议的新治疗方法，包括生物制剂在治疗中日益广泛的使用。FOCIS年会为新的研究人员提供了一个机会，让他们了解基础科学模型的突破在哪里进入临床，以及临床治疗如何应用于完全不同的领域。 除了突出该领域的最佳科学外，FOCIS年会还为发展中的科学家和从业人员提供了一个孵化器，使他们能够沿着相关生物技术和制药行业的代表，他们的共同支持对本次会议的成功至关重要。每天都有海报和口头摘要介绍，让年轻科学家和高级研究人员有机会展示和评论他们的工作。通过彼此分享发现，代表们从学科中获得了研究和应用科学的新想法，否则他们不会在疾病或器官特异性会议上接触到这些新想法。FOCIS年会是一个理想的论坛，让新的研究人员了解不同的翻译方法，这些方法将基础免疫学实验室与临床实践联系起来。除了鼓励新的研究者参与外，FOCIS还认识到广泛的人口统计学参与的重要性。已尽一切努力在FOCIS指导委员会和年会的科学方案中纳入各种代表。在第三届FOCIS年会上，36%的与会者是女性，25%是新的研究人员，25%是少数民族。